Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA)
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis
Sponsor: AP Moeller Foundation
Listed as NCT01119014, this PHASE4 trial focuses on Psychosis and remains completed. Sponsored by AP Moeller Foundation, it has been updated 9 times since 2010, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
May 2025 — Sep 2025 [monthly]
Completed PHASE4
Status: Unknown → Completed
-
Sep 2024 — May 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
▶ Show 4 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Feb 2019 [monthly]
Unknown Status PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE4
First recorded
May 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AP Moeller Foundation
- Albert Einstein College of Medicine
- Allocated inheritance from Elizabeth Stevn and Niels Rindom, Denmark
- Anne Katrine Pagsberg
- Capital Region Pharmacy, Denmark
- Copenhagen Trial Unit, Center for Clinical Intervention Research
- Psychiatric Centre Copenhagen, Denmark
- Research Institute for Biological Psychiatry, Sct. Hans Hospital, Denmark
- The Psychiatric Centre for Children and Adolescents in Bispebjerg, Denmark
- The Research Council for Health and Disease, Denmark
- Tryg Fonden, Denmark
For direct contact, visit the study record on ClinicalTrials.gov .